Press Releases

December 16, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay Additional data shows activity against several variants of concern

PDF Version
December 13, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 22, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 18, 2021 at 8:00 PM EST

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 8, 2021 at 4:00 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment with over 17,000 participants Initiated ~2,000 participant ARCT-154 Phase 3c sub-study to compare immunogenicity noninferiority to AstraZeneca COVID-19 vaccine; enrollment to be completed this week Preparing to

PDF Version
October 25, 2021 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

SAN DIEGO --(BUSINESS WIRE)--Oct. 25, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
October 21, 2021 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Leadership Appointments

SAN DIEGO --(BUSINESS WIRE)--Oct. 21, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
October 20, 2021 at 8:00 PM EDT

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Oct. 20, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
October 12, 2021 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

- Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants - Initiation of Phase 3b study follows review of safety data from initial 1,000 Phase 1/2/3a participants - ARCT-154 remains on track for Emergency Use Authorization (EUA) filing in December 2021 SAN

PDF Version
September 22, 2021 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version